Kodiak Sciences
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1200 Page Mill Rd, Palo Alto, California...Phone Number
(650) 281-0850Website
www.kodiak.comRevenue
-Stock Symbol
KODIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
2
1
1
1
1
About Kodiak Sciences
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, nave macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for retinal inflammatory conditions. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incRead more
Kodiak Sciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Kodiak Sciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Kodiak Sciences is spiking on competitors!
Product Launch: Get notified when Kodiak Sciences launches new products
Check if Kodiak Sciences has recently received funding, and reach out quickly before it becomes old news!
Kodiak Sciences, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Kodiak Sciences recently announced quarterly report
Funding: Get notified immidiatlly once Kodiak Sciences has new funding data
Congratulate Masked Content for being promoted to Masked Content at Kodiak Sciences
Click to see if Kodiak Sciences had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Kodiak Sciences as Masked Content
Find 2 more new buyers
Compare Similar Companies to Kodiak Sciences
Compare insights from companies similar to Kodiak Sciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$114.2M
51-200
Public
$462.1M
1994
JB
Jennifer BuellPresident and CEO of MiNK Therapeutics, Chairman, Executive Council At Agenus
Company Profile Activity
Activity Insights
Kodiak Sciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Kodiak Sciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Kodiak Sciences.
Kodiak Sciences financials insights
Gather financial insights about Kodiak Sciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2009
Other Financing Round
$1.8M
2016
Series B
$34M
2018
Debt
$33M
Stock Offering
$90M
2019
Stock Offering
$317.4M
2020
Debt
$150K
Kodiak Sciences Tech Stack
A closer look at the technologies used by Kodiak Sciences
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Pharmaceuticals
Person-Based
Earnings, Pharmaceuticals, Clinical Operations, Finance
Person-Based
Clinical Operations, Corporate Strategy
Kodiak Sciences News & Media
Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally
This clinical-stage biotech develops innovative retinal disease therapies, with its lead candidate advancing through late-stage trials.Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences
Clinical results of KSI-101 in macular edema secondary to inflammation (MESI) from a tertiary care uveitis practice demonstrate outcomes consistent with results from the U.S. Phase 1b APEX study, supporting continued global development and expansion of the Phase 3 PEAK and PINNACLE...Kodiak Sciences Inc (KOD): What’s the Chance of Success for Zenkuda?
Kodiak Sciences Inc (NASDAQ:KOD) is among the best 52-week high US stocks to buy. On March 27, H.C. Wainwright boosted its price target on Kodiak Sciences Inc (NASDAQ:KOD) to $58 from $38 and reiterated a Buy rating on the shares. The firm raised its price target after positive Phase 3 GLOW2 trial results for tarcocimab […]Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
PALO ALTO, Calif., March 31, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2025. "Kodiak's momentum has continued to build, highlighted by positive Phase 3...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Kodiak Sciences
Sign Up For FreeTo access detailed company insights
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that is in Phase IIb/III clinical study to treat w... Read More
